Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have earned an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay’s lead program includes FPI-1434, […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) CEO John Valliant sold 11,994 shares of Fusion Pharmaceuticals stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $6.41, for a total transaction of $76,881.54. Following the transaction, the chief executive officer now directly owns 328,130 shares in […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) CEO John Valliant sold 2,600 shares of the company’s stock in a transaction on Monday, April 11th. The shares were sold at an average price of $7.37, for a total value of $19,162.00. Following the completion of the sale, the chief executive officer now owns 358,379 shares of […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06, MarketWatch Earnings reports. FUSN opened at $7.35 on Friday. Fusion Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $12.47. The business’s 50-day […]